Antibiotics And Antimycotics Market Scope And Analysis

Report Code : TIPRE00021878
Category : Life Sciences

Status : Published
No. of Pages : 203

Buy Now

Antibiotics and Antimycotics Market Analysis and Growth 2031

Buy Now

Antibiotics and Antimycotics Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 61,207.98 Million
Market Size by 2031	US$ 91,546.07 Million
Global CAGR (2023 - 2031)	5.2%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Drug Class Penicillins Cephalosporins Carbapenems Macrolides Aminoglycosides Quinolones Sulfonamides Tetracyclines Azoles By Indication Skin Infections Respiratory Infections Urinary Tract Infections Septicemia Ear Infections Gastrointestinal Infections By Route of Administration Oral Topical By Distribution Channel Hospital Pharmacies Retail Pharmacies and Drug Stores Online Pharmacies
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Pfizer Inc Novartis AG Sanofi SA F Hoffmann La Roche Ltd Merck Co Inc GSK Plc Johnson Johnson Cipla Ltd Bayer AG

Antibiotics and Antimycotics Market News and Recent Developments

The antibiotics and antimycotics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the antibiotics and antimycotics market are listed below:

Pfizer Inc. received the European Commission (EC) marketing authorization for EMBLAVEO (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections, hospital-acquired pneumonia, and complicated urinary tract infections. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. EMBLAVEO is the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union. (Source: Pfizer Inc, Company Website, April 2024)
Orchid Pharma introduced its new Cefepime-Enmetazobactam drug, which has been approved for the treatment of complicated UTIs, hospital-acquired pneumonia, and ventilator-associated pneumonia indications. In a landmark collaboration, Orchid Pharma partnered with Cipla Limited to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India. (Source: Cipla Ltd, Company Website, June 2024)

Antibiotics and Antimycotics Market Report Coverage and Deliverables

The "Antibiotics and Antimycotics Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

Antibiotics and antimycotics market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Antibiotics and antimycotics market trends, as well as market dynamics such as drivers, restraints, and key opportunities
Detailed PEST and SWOT analysis
Antibiotics and antimycotics market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the antibiotics and antimycotics market
Detailed company profiles